4D Molecular Therapeutics announced positive interim data from the PRISM Phase 2 clinical trials which evaluated intravitreal 4D-150 in a broad wet AMD patient population. The 24-week landmark analysis for the trial reached key efficacy endpoints, including an 89% reduction in mean annualized injection rates. Additionally, 93% of participants received 0 or 1 injections, and 77% were injection-free. These outcomes were achieved with no significant inflammation. Read more: https://lnkd.in/eapkugkk #wetAMD #Ophthalmology #4DMT
Spherix Global Insights
Market Research
Exton, PA 4,011 followers
Invest In Intelligence That Delivers
About us
Spherix Global Insights is a leading provider of market research, business intelligence and advisory services to the global life sciences industry. The company’s unique service offerings are powered by deep therapeutic knowledge, the Spherix Network specialty physician panel, and commercially relevant analyses to enable strategic decision-making by our valued customers. A trusted advisor and industry thought leader, Spherix Global Insights provides specialized market expertise in six (6) focused therapeutic areas including: dermatology, gastroenterology, nephrology, neurology, rheumatology and ophthalmology.
- Website
-
https://www.spherixglobalinsights.com/
External link for Spherix Global Insights
- Industry
- Market Research
- Company size
- 51-200 employees
- Headquarters
- Exton, PA
- Type
- Privately Held
- Founded
- 2015
- Specialties
- Nephrology Insights, Neurology Insights, Rheumatology Insights, Custom Consulting for Specialty Pharma, Healthcare Research, Primary Research, Dermatology Insights, Independent Insights, Gastroenterology Insights, Biopharma, Market Research, Marketing Analytics, Business Intelligence, Big Data, Physician Surveys, Renal Insights, Global Data, Biologics, Multiple Sclerosis, Ophthalmology, Life Sciences, and Immunology Insights
Locations
-
Primary
720 Constitution Drive
2nd Floor
Exton, PA 19341, US
Employees at Spherix Global Insights
-
Pete Kuz
Providing Healthcare Insights that drive Strategy
-
Alissa Algarin
A Leader in Strategic Analytics and Business Intelligence | Passionate about better understanding who we serve, how we market, and how we leverage…
-
Frank Franzino
Insights Director, Neurology at Spherix Global Insights
-
Dan Barton
Chief Executive Officer at Spherix Global Insights
Updates
-
Practical Neurology highlighted recent Spherix research identifying discrepancies in the treatment of those with refractory epilepsy between epileptologists and general neurologists. About 25% of epilepsy patients treated by general neurologists are considered to have refractory epilepsy. While treatment decisions are similar at the time of new-onset seizures, variations in treatments appear after initial treatment fails to control seizures. To gain more insight, read the full article here: https://lnkd.in/gm2tM9HN #Epilepsy #Neurology
-
Today, AbbVie announced the submission of regulatory applications to the FDA and European Medicines Agency for upadacitinib (Rinvoq®) for the treatment of adults with giant cell arteritis (GCA). The submissions are supported by results from the SELECT-GCA Phase 3 study consisting of two periods designed to evaluate the safety and efficacy of upadacitinib in patients with GCA. Read More: https://lnkd.in/eH9GGc2X. #Rheumatology #GCA #Rinvoq #AbbVie
-
Kiniksa Pharmaceuticals has initiated enrollment for a Phase 2b clinical trial of abiprubart in Sjögren’s Disease, an autoimmune disorder lacking FDA-approved therapies. Abiprubart, a humanized anti-CD40 monoclonal antibody, aims to inhibit the CD40-CD154 interaction. The trial will assess treatment response with biweekly and monthly subcutaneous administration compared to placebo over 24 weeks, followed by a 24-week extension phase. Kiniksa emphasizes the potential of abiprubart's convenient administration and expects continued financial stability amidst clinical development. Read more: www. https://lnkd.in/eVU4_AHb #Rheumatology #Abiprubart #SjögrensDisease
-
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) has announced the FDA approval for ZORYVE (roflumilast) cream, 0.15%, a steroid-free treatment for mild to moderate atopic dermatitis (AD) in adults and children, ages 6 years and older. Clinical trials demonstrated its efficacy, safety, and tolerability over 56 weeks of treatment, with significant improvements seen in 90% of patients within 4 weeks and a notable reduction in itch within 24 hours of application. This marks the third FDA approval for Arcutis Biotherapeutics in two years, with commercial availability expected by the end of July. Read more: www. https://lnkd.in/e9yPngnY #Dermatology #AtopicDermatitis #ZORYVE
-
Happy Independence Day from Spherix! Today, we celebrate the freedom that shapes our nation. We wish you a safe and joyful 4th of July! #4thofjuly #independenceday #happyfourth
-
Eli Lilly and Company received FDA approval for Kisunla (donanemab-azbt) for the treatment of adults with early symptomatic Alzheimer's Disease (AD), including mild cognitive impairment and the mild dementia stage of AD. Kisunla, the first and only plaque-targeting therapy using a limited-duration treatment regimen based on amyloid plaque removal, is a once-monthly injection for IV infusion. The approval is based on data from the TRAILBLAZER-ALZ 2 Phase 3 study where Kisunla showed a statistically significant response, with participants seeing up to a 39% lower risk of disease progression compared to placebo. Read more: https://lnkd.in/eF_VjJvy #Alzheimerdisease #EliLilly #Kisunla #donanemab #neurology
-
Formycon AG and Klinge Pharma GmbH have announced FDA approval of FYB203/AHZANTIVE® (aflibercept-mrbb), a biosimilar to Eylea®. FYB203/AHZANTIVE® targets Age-Related Neovascular (wet) Macular Degeneration (nAMD) and other serious retinal conditions by inhibiting Vascular Endothelial Growth Factor (VEGF). The approval was based on a comprehensive data package demonstrating comparable efficacy, safety, pharmacokinetics, and immunogenicity to Eylea®. Formycon AG has also submitted a marketing authorization application for FYB203 to the EMA, expecting a decision by early 2025. Read more: https://lnkd.in/e6Ps5XWw #nAMD #Ophthalmology #FormyconAG #EMA #KlingeBiopharma
-
Apellis Pharmaceuticals, Inc. announced its setback with the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) due to their negative opinion on Apellis' marketing authorization application (MAA) for intravitreal pegcetacoplan, intended for treating geographic atrophy (GA). The decision follows a review emphasizing GA lesion size as a primary trial outcome and microperimetry as a functional measure. Despite multiple dissenting votes within the CHMP, Apellis plans to pursue re-examination, expecting a final decision by the fourth quarter of 2024. Read more: https://lnkd.in/etWNnyXQ #ApellisPharmaceuticals #GeographicAtrophy #AgeRelatedMacularDegeneration #Ophthalmology #GA
-
Roche announced that the European Commission has approved OCREVUS subcutaneous (SC), the first and only twice-a-year injection for relapsing and primary progressive multiple sclerosis (RMS/PPMS). Roche's OCREVUS SC is a 10-minute injection that follows the same administration schedule as the previously approved intravenous (IV) infusion. The European Commission's approval is based on the Phase III OCARINA II trial, which showed non-inferior levels of OCREVUS in the blood, when administered subcutaneously, and a safety and efficacy profile comparable to the IV formulation in patients with RMS and PPMS. More than 92% of patients reported being satisfied or very satisfied with the SC administration of OCREVUS. Read more: https://lnkd.in/ev9iM9Hk. #MS #Neurology #multiplesclerosis #RMS #PPMS